BCL2 and breast carcinoma: GX15–070 (obatoclax), a pan Bcl-2 family inhibitor, cooperated with lapitinib (an EGFR/HER2 inhibitor) to induce cell death in HER2+ breast cancer cells treated with radiotherapies [48].